The Institute for Clinical and Economic Review deemed GLP-1s lacking in cost effectiveness for obesity management in 2022
Progress in biomarker, neuroimaging, and data-science, evolution and implementation of adaptive trial designs, and back-translation from clinical to molecular insights are accelerating the trajectory toward true and clinically effective disease modification
The results of different clinical studies are so far inconclusive and they vary much, depending on experimental design, sample size, health conditions and the chosen rating scale used to asses depressive symptoms in participants
As Retatrutide remains under investigation, researchers are continuing to evaluate the frequency, severity and potential causes of these reactions
Ozempic for Heart, Kidney and Weight Health Ozempics benefits now extend well beyond blood sugar control
In trials, retatrutide produced larger average weight loss (about 24.2% at 48 weeks versus roughly 20.9% for tirzepatide at 72 weeks)